

Alpha-1 Proteinase Inhibitors

| Override(s) | Approval Duration |
|---------------------|-------------------|
| Prior Authorization | 1 Year |

| Medications | Dosing Limit |
|--|------------------------|
| Aralast NP (alpha-1 proteinase inhibitor) | 60 mg/kg once per week |
| Glassia (alpha-1 proteinase inhibitor) | |
| Prolastin-C (alpha-1 proteinase inhibitor) | |
| Zemaira (alpha-1 proteinase inhibitor) | |

APPROVAL CRITERIA

Initial requests for alpha-1 proteinase inhibitor therapy may be approved if the following criteria are met:

- I. Individual has a diagnosis of congenital alpha-1 antitrypsin deficiency (alpha-1 proteinase inhibitor deficiency); **AND**
- II. Documentation is provided that individual's alpha-1 antitrypsin level is less than or equal to 11 $\mu\text{mol/L}$ (approximately equivalent to 80 mg/dL measured by radial immunodiffusion or 57 mg/dL measured by nephelometry) (ATS/ERS, 2003; Stoller, 2017); **AND**
- III. Individual has clinically evident emphysema (or chronic obstructive pulmonary disease [COPD]); **AND**
- IV. Individual is currently a non-smoker (ATS/ERS, 2003; CTS, 2013); **AND**
- V. One of the following:
 - A. Documentation is provided that individual has moderate airflow obstruction evidenced by a forced expiratory volume (FEV_1) of 30-65% of predicted value prior to initiation of therapy (ATS/ERS, 2003); **OR**
 - B. Documentation is provided that individual has a rapid decline in lung function as measured by a change in FEV_1 greater than 120 mL/year (ATS/ERS, 2003); **AND**
- VI. Individual meets one of the following:
 - A. Individual is not IgA deficient; **OR**
 - B. Individual is IgA deficient and does not have antibodies to IgA.

Continuation requests for alpha-1 proteinase inhibitor therapy may be approved if the following criteria are met:

- I. Documentation is provided that there is clinically significant improvement or stabilization in clinical signs and symptoms of disease (including but not limited to decreased frequency of exacerbations, slowed rate of FEV_1 decline, preservation of CT scan lung density or improvement in symptom burden); **AND**
- II. Individual remains a non-smoker.

Alpha-1 proteinase inhibitor therapy may not be approved when the above criteria are not met and for all other indications.

Key References:

1. American Thoracic Society(ATS)/European Respiratory Society (ERS) Statement: Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency. Am J Respir Crit Care Med. 2003; 168(7):818-900.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: January 15, 2025.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc. Updated periodically.
5. Marciniuk DD, Hernandez P, Balter M, et al. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2012; 19(2):109-116.
6. Stoller JK. Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency. Updated: October 1, 2024. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. Accessed: January 14, 2025.
7. Stoller JK. Treatment of emphysema from alpha-1 antitrypsin deficiency. Updated: April 16, 2024. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. Accessed: January 14, 2025.
8. Stoller JK, Hupertz V, Aboussouan LS. Alpha-1 Antitrypsin Deficiency. GeneReviews (online). University of Washington, Seattle. Updated: June 1, 2023. Available at: <http://www.ncbi.nlm.nih.gov/books/NBK1519/?report=classic>. Accessed: January 15, 2025.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.